These findings deepen the mechanistic understanding of ccRCC angiogenesis and underscore the ERβ/circAHNAK/FMR1/ADAM17 axis as a promising therapeutic target. The gene discussed is FMR1; the disease is nonpapillary renal cell carcinoma.